AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
DF
Drug FarmDrug Farm is a biotech developing AI-designed small-molecule drugs for rare and immune-inflammatory diseases, led by DF-003, a Phase 3 ALPK1 inhibitor for ROSAH syndrome.
2 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
$138M
Attovia TherapeuticsDrug Farm
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Attovia TherapeuticsDrug Farm
Biotech
Sector
Biotech
2023
Founded
2015
San Carlos, CA
HQ
Shanghai, China / New York, NY
Public (ATTO)
Status
Private
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Drug Farm investors
Shanghai Pudong Leading Area Investment CenterShanghai Puxing Collaborative Private Equity FundDetong CapitalWuXi AppTecBioVeda China FundYD CapitalBetta CapitalWedo Venture Management
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Drug Farm.